Today: 21 May 2026
AT&T stock nudges up after $1.02 billion spectrum deal closes as earnings loom
15 January 2026
1 min read

AT&T stock nudges up after $1.02 billion spectrum deal closes as earnings loom

New York, Jan 15, 2026, 14:36 EST — Regular session.

  • AT&T shares rose roughly 0.3% in afternoon trading, while Verizon and T-Mobile edged lower
  • According to an SEC filing, AT&T completed a $1.018 billion deal to acquire spectrum from Array Digital Infrastructure
  • Bernstein names AT&T its leading U.S. telecom pick for 2026 amid mounting price pressure

AT&T Inc. shares ticked up Thursday following a regulatory filing that revealed the company wrapped up a $1.018 billion deal for spectrum licenses. The move signals a push to boost network capacity ahead of a packed earnings season for U.S. telecoms. The stock gained roughly 0.3% to $23.69 in afternoon trading.

The airwaves are the essential asset. While more spectrum can boost coverage and increase bandwidth, it also means higher costs—something investors are closely monitoring amid concerns over the stability of U.S. wireless pricing.

This is key as carriers push bundles—wireless combined with home internet—to hold onto customers amid rising promotions. AT&T is working to boost fiber growth and maintain steady cash flow, all while fending off Verizon and T-Mobile.

Array Digital Infrastructure, which used to operate as United States Cellular, finalized its sale to AT&T for $1.018 billion in cash on Jan. 13. The deal included part of Array’s retained spectrum licenses and was accompanied by a special dividend announcement from the company.

The Form 8-K filing identified the buyer as New Cingular Wireless PCS, LLC, a subsidiary of AT&T, noting the $1.018 billion deal was settled in cash at closing. It also specified that $232 million of the total was assigned to certain 700 MHz band licenses now fully owned by Array through its 100% equity stake.

The 700 MHz band, known for traveling longer distances and better building penetration, is part of the frequencies involved. In contrast, 3.45 GHz sits in the mid-band range and supports higher data capacity, making it valuable for 5G and fixed wireless services.

Bernstein analyst Laurent Yoon has pegged AT&T as his top U.S. telecom pick for 2026, despite flagging a “new era of competition” ahead. He highlighted steep rate cuts from Verizon and Comcast as a clear sign that “the gloves are off.” Still, Yoon believes AT&T can continue growing fiber and fixed wireless access — broadband delivered via mobile networks. Investing.com

More spectrum doesn’t guarantee a clear advantage if it sparks a price war. Increased promotions and faster customer churn could squeeze service margins and tighten cash flow — a tough spot for a high-dividend stock that continues to invest heavily in its networks.

Investors will get a clearer picture on Jan. 28, when AT&T reports its fourth-quarter 2025 results and holds a conference call. Traders are focused on postpaid phone net additions, broadband performance, free cash flow, and any updates to 2026 spending forecasts and guidance.

Stock Market Today

  • EnerSys Q1 CY2026 Sales Beat Estimates with Optimistic Guidance
    May 20, 2026, 6:18 PM EDT. Battery maker EnerSys (NYSE:ENS) reported Q1 CY2026 sales of $988 million, up 1.4% year on year, beating analyst estimates by 1.5%. Adjusted earnings per share (EPS) stood at $3.19, a 6.6% beat over consensus. Guidance for Q2 revenue is $935 million, 2.2% above estimates, with adjusted EPS guidance also exceeding forecasts. Despite a 6% decline in sales volumes, revenue growth was supported by price increases. Free cash flow turned negative at -$12.66 million, down from $105 million last year. EnerSys continues to push its lithium data center and battery energy storage system solutions, signaling long-term innovation. The company's subdued 4.7% annualized revenue growth over five years contrasts with sector expectations, raising caution among investors.

Latest articles

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

AEVEX Stock Jumps After Hours as Drone Maker Posts 307% Revenue Surge and New Air Force Deal

21 May 2026
AEVEX Corp. shares surged over 10% after hours Wednesday following a first-quarter profit of $21 million and new U.S. Air Force contracts worth $15.6 million. Revenue jumped to $216.7 million, beating estimates. The company, which went public in April, raised its full-year revenue outlook to $600–$620 million. The stock had closed regular trading at $26.27, down 0.23%.
Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

Jupiter Neurosciences Stock Swings on $100M MDMA Pact, $2M Equity Sale

21 May 2026
Jupiter Neurosciences shares fell 37% to $0.205 Wednesday after announcing a proposed U.S. licensing deal for PharmAla Biotech’s MDMA-based ALA-002 and a $2 million stock offering. Trading volume topped 230 million shares. The licensing agreement is non-binding, with a potential value over $100 million, and gives Jupiter 90 days to finalize terms. Jupiter reported a $2.06 million Q1 net loss and $2.36 million in cash.
Urban Outfitters Stock Swings After Record Q1—What Nuuly and Tariffs Are Telling Investors

Urban Outfitters Stock Swings After Record Q1—What Nuuly and Tariffs Are Telling Investors

21 May 2026
Urban Outfitters posted record first-quarter net income of $115.7 million and sales of $1.48 billion, beating analyst estimates. Shares closed up 4.05% at $71.67 before slipping to $70.55 in after-hours trading. Comparable retail sales rose 5.6%, with strong gains at FP Group, Urban Outfitters, and Nuuly. Gross profit rate edged down to 36.6% as tariffs pressured costs.
Opendoor Technologies stock slips today as mortgage applications surge and Treasuries stay stubborn
Previous Story

Opendoor Technologies stock slips today as mortgage applications surge and Treasuries stay stubborn

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead
Next Story

Philip Morris stock edges up after PMI flags $20B+ U.S. investment push, FDA ZYN review ahead

Go toTop